Holodiag, provider of solid state solutions, and Holochem, provider of chemical and process development services, have partnered to supply their customers with a full range of integrated fine chemical and active pharmaceutical ingredient (API) contract development and manufacturing services, through all stages of the drug development lifecycle.

Holodiag is a contract research organization (CRO) recognized for its know-how in the field of pharmaceutical solid state. Over the last years the company has increasingly focused on R&D, and the new partnership with Holochem is in line with this strategic direction.

Holochem’s areas of expertise cover the chemical, process and analytical development phases of key intermediates and APIs.

“Our offers are complementary and we were both seduced by the prospect of offering our customers a wider array of services,” said Serge Calet, founder and chief executive officer, Holochem. “The idea arose quite naturally to collaborate with the objective to jointly offer integrated CMC services.”

Pierric Marchand, founder and chief executive officer, Holodiag, said, “What makes the partnership work is our matching business approach. We focus on building long-term relationships, and this won’t change for our current customers who continue to benefit from the same customer-tailored solutions and personalized support, while gaining access to additional R&D services whenever needed.”

Holodiag and Holochem will jointly exhibit at CPhI Worldwide October 24-26 in Frankfurt at stand #41D50.